Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

<p>Abstract</p> <p>Background</p> <p>The incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe due to MPM will increase until 2020. Despite progress in chemo-...

Full description

Bibliographic Details
Main Authors: Felley-Bosco Emanuela, Kurtz Stefanie, Hopkins-Donaldson Sally, Marti Thomas M, Belyanskaya Larisa L, Stahel Rolf A
Format: Article
Language:English
Published: BMC 2007-10-01
Series:Molecular Cancer
Online Access:http://www.molecular-cancer.com/content/6/1/66

Similar Items

Similar Items